Research graph
References from Epigenetic programming via lysine-specific demethylase 1 regulates responses to immune checkpoint blockade. Local targets link to admitted publications; unresolved targets remain external evidence.
Immune checkpoint blockade: a common denominator approach to cancer therapy
10.1016/j.ccell.2015.03.001 · 2015 · External reference
Cancer immunotherapy using checkpoint blockade
10.1126/science.aar4060 · 2018 · External reference
Primary, adaptive, and acquired resistance to cancer immunotherapy
10.1016/j.cell.2017.01.017 · 2017 · External reference
Tumour-intrinsic resistance to immune checkpoint blockade
10.1038/s41577-019-0218-4 · 2020 · External reference
Targeting the epigenetic regulation of antitumour immunity
10.1038/s41573-020-0077-5 · 2020 · External reference
LSD1: an emerging face in altering the tumor microenvironment and enhancing immune checkpoint therapy
10.1186/s12929-023-00952-0 · 2023 · External reference
Leveraging non-enzymatic functions of LSD1 for novel therapeutics
10.1016/j.tips.2025.01.006 · 2025 · External reference
LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade
10.1016/j.cell.2018.05.052 · 2018 · External reference
Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade
10.1038/s41388-018-0451-5 · 2019 · External reference
LSD1 inhibition induces MHC-I and dendritic cell activation to promote antitumor immunity in head and neck squamous cell carcinoma
10.1158/0008-5472.can-24-3239 · 2026 · External reference
Inhibiting LSD1 unlocks retinoid AP-1 programming to activate epithelial immunity and skin tumor suppression
10.1172/jci189044 · 2026 · External reference
LSD1 inhibitor, TAS1440, disrupts INSM1-LSD1 complex activating tumor-suppressive pathways via transcriptional reprogramming in neuroendocrine SCLC
10.1038/s41467-026-70984-1 · 2026 · External reference
LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer
10.1186/s12943-022-01557-1 · 2022 · External reference
LSD1 inhibition attenuates targeted therapy-induced lineage plasticity in BRAF mutant colorectal cancer
10.1186/s12943-025-02311-z · 2025 · External reference
Priming with LSD1 inhibitors promotes the persistence and antitumor effect of adoptively transferred T cells
10.1038/s41467-024-48607-4 · 2024 · External reference
LSD1 inhibition improves efficacy of adoptive T cell therapy by enhancing CD8+ T cell responsiveness
10.1038/s41467-024-51500-9 · 2024 · External reference
Inhibitory PD-1 axis maintains high-avidity stem-like CD8+ T cells
10.1038/s41586-025-09440-x · 2026 · External reference
Regulation of T cell exhaustion and stemness: molecular mechanisms and implications for cancer immunotherapy
10.1038/s41423-025-01378-4 · 2026 · External reference
Targeting lysine-specific demethylase 1 rescues major histocompatibility complex class I antigen presentation and overcomes programmed death-ligand 1 blockade resistance in SCLC
10.1016/j.jtho.2022.05.014 · 2022 · External reference
Epigenetic therapy potentiates transposable element transcription to create tumor-enriched antigens in glioblastoma cells
10.1038/s41588-024-01880-x · 2024 · External reference
Lysine-specific demethylase 1 controls key OSCC preneoplasia inducer STAT3 through CDK7 phosphorylation during oncogenic progression and immunosuppression
10.1038/s41368-025-00363-x · 2025 · External reference
DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts
10.1016/j.cell.2015.07.056 · 2015 · External reference
KDM1A epigenetically enhances RAD51 expression to suppress the STING-associated anti-tumor immunity in esophageal squamous cell carcinoma
10.1038/s41419-024-07275-4 · 2024 · External reference
Inhibition of LSD1 attenuates oral cancer development and promotes therapeutic efficacy of immune checkpoint blockade and YAP/TAZ inhibition
10.1158/1541-7786.mcr-21-0310 · 2022 · External reference
Inhibition of lysine-specific demethylase 1 (LSD1) prevented tumor growth and metastasis by downregulating PD-L1 expression in lung adenocarcinoma
10.1016/j.gendis.2022.11.002 · 2023 · External reference
LSD1 silencing contributes to enhanced efficacy of anti-CD47/PD-L1 immunotherapy in cervical cancer
10.1038/s41419-021-03556-4 · 2021 · External reference
Id2 epigenetically controls CD8+ T-cell exhaustion by disrupting the assembly of the Tcf3-LSD1 complex
10.1038/s41423-023-01118-6 · 2024 · External reference
LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation
10.1016/j.immuni.2024.01.010 · 2024 · External reference
Vista as a context-dependent immune checkpoint: implications for tumor immunity and autoimmune pathogenesis
10.1016/j.bbcan.2025.189351 · 2025 · External reference
Inhibiting the coregulator CoREST impairs Foxp3+ Treg function and promotes antitumor immunity
10.1172/jci131375 · 2020 · External reference
Targeting nuclear LSD1 to reprogram cancer cells and reinvigorate exhausted T cells via a novel LSD1-EOMES switch
10.3389/fimmu.2020.01228 · 2020 · External reference
Stepwise epigenetic signal integration drives adaptive programming of cytotoxic lymphocytes
10.1016/j.immuni.2026.01.004 · 2026 · External reference
Integrated epigenetic and genetic programming of primary human T cells
10.1038/s41587-025-02856-w · 2025 · External reference
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
10.1038/nature19330 · 2016 · External reference
Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
10.1126/science.aaf2807 · 2016 · External reference
Lysine-specific demethylase 1 regulates hematopoietic stem cell expansion and myeloid cell differentiation
10.1038/s41419-025-07951-z · 2025 · External reference
Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes
10.1080/10428194.2021.2012667 · 2022 · External reference
Phase 2 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat for essential thrombocythemia
10.1182/bloodadvances.2025017575 · 2026 · External reference
Inhibition of LSD1 in MDS progenitors restores differentiation of CD141Hi conventional dendritic cells
10.1038/s41375-020-0765-5 · 2020 · External reference
Phase I, open-label, dose-escalation study of the safety, pharmacokinetics, pharmacodynamics, and efficacy of GSK2879552 in relapsed/refractory SCLC
10.1016/j.jtho.2019.06.021 · 2019 · External reference
Epigenetic regulation of hematopoietic differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors CoREST and LSD1
10.1016/j.molcel.2007.06.039 · 2007 · External reference
A novel LSD1 inhibitor T-3775440 disrupts GFI1B-containing complex leading to transdifferentiation and impaired growth of AML cells
10.1158/1535-7163.mct-16-0471 · 2017 · External reference
T-448, a specific inhibitor of LSD1 enzyme activity, improves learning function without causing thrombocytopenia in mice
10.1038/s41386-018-0300-9 · 2019 · External reference
Design, synthesis, and structure-activity relationship of TAK-418 and its derivatives as a novel series of LSD1 inhibitors with lowered risk of hematological side effects
10.1016/j.ejmech.2022.114522 · 2022 · External reference
Inhibition of LSD1 with bomedemstat sensitizes small cell lung cancer to immune checkpoint blockade and T-cell killing
10.1158/1078-0432.ccr-22-1128 · 2022 · External reference
Landscape and treatment options of shapeshifting small cell lung cancer
10.3390/jcm13113120 · 2024 · External reference
Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential
10.3389/fimmu.2023.1214675 · 2023 · External reference
TNG260 is a small-molecule CoREST inhibitor that sensitizes STK11-mutant tumors to anti-PD-1 immunotherapy
10.1158/0008-5472.can-25-0998 · 2025 · External reference
JBI-802: the first orally available LSD1/HDAC6 dual inhibitor to enter clinical trials
10.1080/13543776.2025.2468792 · 2025 · External reference
Optimizing early-phase immunotherapy trials: the role of biomarker enrichment strategies
10.3389/fimmu.2025.1664443 · 2025 · External reference
E3 ligase Trim35 inhibits LSD1 demethylase activity through K63-linked ubiquitination and enhances anti-tumor immunity in NSCLC
10.1016/j.celrep.2023.113477 · 2023 · External reference
USP22 drives tumor immune evasion and checkpoint blockade resistance through EZH2-mediated epigenetic silencing of MHC-I
10.1172/jci193162 · 2026 · External reference
TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumors
10.1016/j.ccell.2025.09.011 · 2026 · External reference
Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses
10.1016/j.cell.2015.07.011 · 2015 · External reference
Pluripotent stem cell protein Sox2 confers sensitivity to LSD1 inhibition in cancer cells
10.1016/j.celrep.2013.09.018 · 2013 · External reference
The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes
10.18632/aging.102887 · 2020 · External reference
Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1
10.1038/s41467-022-31998-7 · 2022 · External reference
Lymph-node-derived stem-like but not tumor-tissue-resident CD8+ T cells fuel anticancer immunity
10.1038/s41590-025-02219-2 · 2025 · External reference
Lactylation of LSD1 is an acquired epigenetic vulnerability of BRAFi/MEKi-resistant melanoma
10.1016/j.devcel.2025.02.016 · 2025 · External reference
Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities
10.1016/j.tips.2024.04.006 · 2024 · External reference
Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade
10.1016/j.cell.2016.11.022 · 2016 · External reference
Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction
2023 · External reference
Discovery of an LSD1 PROTAC degrader
10.1073/pnas.2425812122 · 2025 · External reference
